Elsiglutide/ZP1846
Glucagon-like Peptide-2 (GLP-2) is a peptide growth factor that specifically targets and stimulates growth of the intestinal epithelium. GLP-2 is a naturally occurring peptide hormone produced primarily by the small intestine. It is secreted in response to food ingestion and acts by binding to the GLP-2 receptor, which is predominantly found in the gastrointestinal tract. GLP-2 plays a key role in intestinal growth and formation by promoting regeneration of the epithelial surface damaged by chemotherapy, the underlying cause of CID.
Elsiglutide (ZP1846) is a SIP® modified novel GLP-2 peptide analogue with enhanced stability and efficacy. In pre-clinical pharmacological studies, Elsiglutide consistently stimulates growth of the small intestinal mucosa and decreases the incidence and severity of Chemotherapy-Induced Diarrhea (CID).
It is anticipated that use of Elsiglutide may ameliorate or prevent the destructive effects of chemotherapy on the small intestine and thereby reduce the incidence of diarrhea. Based on the Company’s pre-clinical data a Phase IIa clinical evaluation in healthy volunteers was finalized in 2008 in the U.S.
Elsiglutide was outlicensed to Helsinn Healthcare S.A. in November 2008.
Helsinn Healthcare is currently conducting a Phase Ib trial in five centers in Europe involving colorectal cancer patients.
Tip a friend
Fill in the form below to tip a friend about this page.
Subscribe
When this page is updated you will be updated by e-mail.
Home Legal Disclaimer Updated: 21.2.2012